Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de fase 1 de GTX-B001 en subjetos sanos y pacientes con urticaria fría (CHILL-MC)

17 de noviembre de 2026 actualizado por: Granular Therapeutics Limited

Un ensayo de dosis ascendente de fase 1, aleatorizado, doble ciego, controlado con placebo, un ensayo de eficacia ascendente simple de GTX-B001 en voluntarios sanos (Parte A) y pacientes con urticaria inducida por el frío (Parte B)

This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.

Descripción general del estudio

Descripción detallada

GTX-B001 is a humanized bispecific antibody than binds with one arm to a protein called c-Kit and with the second arm to a protein called CD203c, both expressed on mast cells.

This study is a randomized, double-bind, placebo-controlled phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of a single dose of GTX-B001 in healthy participants (Part A) and in patients with chronic inducible urticaria (cold urticaria and symptomatic dermographism) who remain symptomatic despite treatment with antihistamines (Part B). In part B, the preliminary efficacy of GTX-B001 on the signs and symptoms of chronic inducible urticaria will also be evaluated.

48 healthy participants are estimated to be enrolled in part A in five ascending cohorts, while 24 patients with chronic inducible urticaria are estimated to be enrolled in Part B in two ascending cohorts.

Potential participants will be screened for up to 4 weeks prior to enrollment. GTX-B001 will be administered intravenously on Day 1 to randomized participants who will be followed for 12 weeks post-treatment.

Participants will be required to attend a total of 9 visits including the screening visit.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

72

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Berlin, Alemania
        • Reclutamiento
        • Charite Universitaetsmedizin Berlin
        • Contacto:
      • Berlin, Alemania
        • Activo, no reclutando
        • Charité Research Organization gmbh
      • Halle, Alemania
        • Reclutamiento
        • Dermatologische Praxis
        • Contacto:
      • Marburg, Alemania
        • Reclutamiento
        • Universitaetsklinikum Giessen und Marburg GmbH
        • Contacto:
      • Münster, Alemania
        • Reclutamiento
        • Universitatsklinikum Münster
        • Contacto:
          • Principal Investigator
          • Número de teléfono: +492518355555
          • Correo electrónico: derma@ukmuenster.de
      • Tübingen, Alemania

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Descripción

Key inclusion Criteria (Part A):

  • The subject is between 18 and 55 years of age (both inclusive) at the date of screening.
  • The subject is in good general health based on the medical history, physical examination and the results of vital signs, electrocardiogram and clinical laboratory, as judged by the investigator.

Key inclusion Criteria (Part B):

  • The subject is between 18 and 75 years of age (both inclusive) at the date of screening
  • A history of signs and/or symptoms of ColdU or SD experienced ≥ 3 months prior to screening.
  • For ColdU patients, a positive provocation test during screening and baseline, using the TempTest® device.
  • For SD patients, a positive provocation test with at least 3 pins during screening and baseline, using the FricTest® device.
  • Inadequate control of ColdU or SD by second generation H1-antihistamine (sgAH) as defined as the presence of itch and hives following a trigger (e.g. cold or scratching, respectively) within the last 6 weeks prior to screening in spite of use of a sgAH.
  • A Urticaria Control Test (UCT) score of < 12 at screening.

Key exclusion Criteria (Parts A & B):

  • Presence of any clinically significant illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, or endocrine disease or disorder that would interfere with the patient's safety or the interpretation of trial results in the judgment of the investigator.
  • Treatment with an investigational drug or intervention for any condition within three months of screening, or concurrent participation in another clinical trial in which an investigational drug is administered.
  • Treatment with immunomodulating therapy (e.g., intravenous or intramuscular immunoglobulins, systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus, mycophenolate mofetil, hydroxychloroquine, infliximab, adalimumab, etanercept, etc.) within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.
  • Use of any monoclonal antibody or therapeutic protein within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.
  • History of anaphylaxis, autoimmune disorders requiring more than topical medication, or asthma requiring regular use of inhaled medication within the past 5 years, unless, in the opinion of the Investigator, the condition is not considered clinically significant and is unlikely to affect subject safety or study outcomes.

Additionally for Part B:

  • Disease with symptoms of urticaria or angioedema other than Chronic Urticaria (CU), for example urticaria vasculitis, erythema multiforme, mastocytosis, or drug-induced urticaria. Patients with concomitant Chronic Spontaneous Urticaria (CSU) or other forms of Chronic Inducible Urticaria (CIndU) are eligible provided that symptoms at screening are consistent with ColdU or SD and that ColdU or SD is the dominant form of CU.
  • Any other skin disease associated with chronic itching that might influence in the investigators' opinion of the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or psoriasis.
  • Receipt of any biologic therapy for urticaria control (e.g. omalizumab, dupilumab, ligelizumab, etc.) within three months of screening (whether on-label or off-label).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part A (HV) - GTX-B001

Healthy participants will receive a single dose of GTX-B001

Single infusion of one of up to five dosages of GTX-B001

Otros nombres:
  • Aly-301
Comparador de placebos: Part A (HV) - Normal Saline

Healthy participants assigned to receive placebo will receive a single dose of normal saline

Single infusion of normal saline

Experimental: Part B (ColdU/SD) - GTX-B001

Patients with cold urticaria or symptomatic dermographism will receive a single dose of GTX-B001

Single infusion of one of up to five dosages of GTX-B001

Otros nombres:
  • Aly-301
Comparador de placebos: Part B (ColdU/SD) - Normal Saline

Patients with cold urticaria or symptomatic dermographism assigned to receive placebo will receive a single dose of normal saline

Single infusion of normal saline

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety as assessed by the incidence and severity of adverse events (Parts A and B)
Periodo de tiempo: Day 1 to Day 85

Safety and tolerability of a single intravenous infusion of GTX-B001 as assessed by the percentage of subjects at each dose level with Grade 2 or higher adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE).

Day 1 to Day 85

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
GTX-B001 pharmacokinetics (Parts A and B)
Periodo de tiempo: Day 1 to Day 85

Serum concentrations of GTX-B001 at specified visits

Day 1 to Day 85

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
GTX-B001 pharmacodynamics (Parts A and B)
Periodo de tiempo: Day 1 to Day 85

Change from baseline in blood biomarkers such as serum tryptase

Day 1 to Day 85
GTX-B001 pharmacodynamics in skin (Part B)
Periodo de tiempo: Day 1 to Day 29

Change from baseline in mast cell density and mast cell activation markers upon cold or friction provocation, assessed from skin punch biopsy at baseline and three times post-treatment.

Day 1 to Day 29
Evaluation of immunogenicity (Parts A and B)
Periodo de tiempo: Day 1 to Day 85

Incidence of anti-drug antibodies

Day 1 to Day 85
Disease control (Part B ColdU) - Critical Temperature Threshold (CTT)
Periodo de tiempo: Day 1 to Day 85

Change from baseline and percentage of responders in Critical Temperature Threshold (CTT) over time as determined by provocation testing using the TempTest®. The CTT determines the highest temperature that induces symptoms.

Day 1 to Day 85
Disease control (Part B SD) - Critical Friction Threshold (CFT)
Periodo de tiempo: Day 1 to Day 85

Change from baseline and percentage of responders in Critical Friction Threshold (CFT) over time as determined by provocation testing using the FricTest®. The CFT determines the shortest pin length (or lowest pressure) that induces symptoms.

Day 1 to Day 85
Disease control (Part B) - Urticaria Control Test (UCT)
Periodo de tiempo: Day 1 to Day 85

Change from baseline and percentage of responders for the Urticaria Control Test (UCT). Total score ranges from 0 to 16. A score of 12 or higher indicates well-controlled chronic urticaria, while a score below 12 suggests poorly controlled disease.

Day 1 to Day 85
Disease control (Part B ColdU) - Cold Urticaria Activity Score (Cold UAS)
Periodo de tiempo: Day 1 to Day 85

Change from baseline in Cold Urticaria Activity Score (Cold UAS). The total score ranges from 0 to 6, the higher the score the higher the disease activity.

Day 1 to Day 85
Disease control (Part B SD) - Symptomatic Dermographism Activity Score (SDAS)
Periodo de tiempo: Day 1 to Day 85

Change from baseline in Symptomatic Dermographism Activity Score (SDAS)

Day 1 to Day 85
Disease control (Part B ColdU) - Cold Urticaria Quality of Life Questionnaire (ColdU-QoL)
Periodo de tiempo: Day 1 to Day 85

Change from baseline in Cold Urticaria Quality of Life Questionnaire (ColdU-QoL). The total score ranges from 0 to 100, the higher the score the higher the impairment.

Day 1 to Day 85
Disease control (Part B SD) - Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL)
Periodo de tiempo: Day 1 to Day 85

Change from baseline in Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL). The total score ranges from 0 to 100, the higher the score the higher the impairment.

Day 1 to Day 85

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

6 de octubre de 2025

Finalización primaria (Estimado)

1 de agosto de 2027

Finalización del estudio (Estimado)

1 de agosto de 2027

Fechas de registro del estudio

Enviado por primera vez

12 de septiembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

12 de septiembre de 2025

Publicado por primera vez (Actual)

18 de septiembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

17 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir